Summary of Study ST002922

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001814. The data can be accessed directly via it's Project DOI: 10.21228/M87D9M This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002922
Study TitleEffects of DINCH and MINCH on adipocyte metabolism of human SGBS cells.
Study SummaryIn the first part of the project, we investigated the effects of DINCH and MINCH on central carbon metabolism. For this purpose, the human SGBS preadipocyte cell line (Wabitsch et al., 2001) was exposed to DINCH and MINCH at concentrations ranging from 10 nM to 10 µM and compared with cells differentiated with rosiglitazone (adipogenic reference) and without rosiglitazone (undifferentiated control). Analysis of central carbon metabolism showed that MINCH, similar to rosiglitazone, induces lipid accumulation mainly through PPARG-mediated upregulation of the pyruvate cycle. In addition, increased lactate production suggests altered glucose homeostasis induced by MINCH-treatment. Our results suggest that MINCH could potentially lead to a weight-promoting effect, as observed with thiazolidinediones, because of the similarity of the observed changes to the effects of the thiazolidinedione rosiglitazone.
Helmholtz Centre for Environmental Research
DepartmentMolecular Systems Biology
Last NameEngelmann
First NameBeatrice
AddressPermoserstraße 15, Leipzipg, Saxony, 03418, Germany
Submit Date2023-10-04
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2023-11-03
Release Version1
Beatrice Engelmann Beatrice Engelmann application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR001814
Project DOI:doi: 10.21228/M87D9M
Project Title:MINCH causes metabolic rewiring towards lipid accumulation and adipogenesis
Project Summary:Humans are ubiquitously exposed to plastic additives, including plasticizers. There is growing evidence that exposure to certain plasticizers is associated with the development of obesity due to their metabolism-disrupting properties. Following the restriction of the use of the phthalate plasticizer di-(2-ethylhexyl) phthalate (DEHP) due to its adverse health effects, it has been replaced by new substitutes such as the plasticizer diisononylcyclohexane-1,2-dicarboxylate (DINCH). Despite recent studies suggesting that the primary metabolite monoisononylcyclohexane-1,2-dicarboxylic acid ester (MINCH) promotes human adipocyte differentiation, the adipogenic properties of MINCH remain controversial. Because the metabolome largely reflects the molecular phenotype and is sensitive to perturbation by external factors, we used targeted metabolomics to investigate the effects of DINCH and MINCH on key metabolic pathways of adipocytes. Analysis of central carbon metabolism is particularly relevant because it provides cellular energy through the degradation of organic compounds and metabolic precursors for anabolic functions that are critical for adipocyte function, such as de novo lipogenesis. The project consists of three main studies: analysis of the effects of DINCH and MINCH on central carbon metabolism of human SGSB cells, analysis of the insulin response of DINCH- and MINCH-treated SGSB cells, and analysis of the effects of DINCH and MINCH on central carbon metabolism of human SGSB cells in the presence of the PPARG inhibitor GW9662.
Institute:Helmholtz Centre for Environmental Research
Last Name:Engelmann
First Name:Beatrice
Address:Permoserstr. 15


Subject ID:SU003035
Subject Type:Cultured cells
Subject Species:Homo sapiens
Taxonomy ID:9606


Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment
SA317312Ctrl_SN2Control supernatant
SA317313Ctrl_SN3Control supernatant
SA317314Ctrl_SN1Control supernatant
SA317315Ctrl_SN4Control supernatant
SA317316DINCH_100nM_2DINCH 100nM
SA317317DINCH_100nM_3DINCH 100nM
SA317318DINCH_100nM_1DINCH 100nM
SA317319DINCH_100nM_4DINCH 100nM
SA317320DINCH_100nM_SN3DINCH 100nM supernatant
SA317321DINCH_100nM_SN2DINCH 100nM supernatant
SA317322DINCH_100nM_SN1DINCH 100nM supernatant
SA317323DINCH_100nM_SN4DINCH 100nM supernatant
SA317332DINCH_10uM_2DINCH 10µM
SA317333DINCH_10uM_3DINCH 10µM
SA317334DINCH_10uM_4DINCH 10µM
SA317335DINCH_10uM_1DINCH 10µM
SA317336DINCH_10uM_SN1DINCH 10µM supernatant
SA317337DINCH_10uM_SN3DINCH 10µM supernatant
SA317338DINCH_10uM_SN2DINCH 10µM supernatant
SA317339DINCH_10uM_SN4DINCH 10µM supernatant
SA317324DINCH_10nM_2DINCH 10nM
SA317325DINCH_10nM_1DINCH 10nM
SA317326DINCH_10nM_3DINCH 10nM
SA317327DINCH_10nM_4DINCH 10nM
SA317328DINCH_10nM_SN3DINCH 10nM supernatant
SA317329DINCH_10nM_SN2DINCH 10nM supernatant
SA317330DINCH_10nM_SN4DINCH 10nM supernatant
SA317331DINCH_10nM_SN1DINCH 10nM supernatant
SA317340DINCH_1uM_2DINCH 1µM
SA317341DINCH_1uM_4DINCH 1µM
SA317342DINCH_1uM_3DINCH 1µM
SA317343DINCH_1uM_1DINCH 1µM
SA317344DINCH_1uM_SN3DINCH 1µM supernatant
SA317345DINCH_1uM_SN2DINCH 1µM supernatant
SA317346DINCH_1uM_SN4DINCH 1µM supernatant
SA317347DINCH_1uM_SN1DINCH 1µM supernatant
SA317384MINCH_10uM_blank3Medium blank supernatant
SA317385MINCH_10uM_blank2Medium blank supernatant
SA317386MINCH_10uM_blank1Medium blank supernatant
SA317348MINCH_100nM_4MINCH 100nM
SA317349MINCH_100nM_2MINCH 100nM
SA317350MINCH_100nM_1MINCH 100nM
SA317351MINCH_100nM_3MINCH 100nM
SA317352MINCH_100nM_SN4MINCH 100nM supernatant
SA317353MINCH_100nM_SN2MINCH 100nM supernatant
SA317354MINCH_100nM_SN3MINCH 100nM supernatant
SA317355MINCH_100nM_SN1MINCH 100nM supernatant
SA317364MINCH_10uM_2MINCH 10µM
SA317365MINCH_10uM_3MINCH 10µM
SA317366MINCH_10uM_4MINCH 10µM
SA317367MINCH_10uM_1MINCH 10µM
SA317368MINCH_10uM_SN2MINCH 10µM supernatant
SA317369MINCH_10uM_SN3MINCH 10µM supernatant
SA317370MINCH_10uM_SN4MINCH 10µM supernatant
SA317371MINCH_10uM_SN1MINCH 10µM supernatant
SA317356MINCH_10nM_3MINCH 10nM
SA317357MINCH_10nM_1MINCH 10nM
SA317358MINCH_10nM_4MINCH 10nM
SA317359MINCH_10nM_2MINCH 10nM
SA317360MINCH_10nM_SN3MINCH 10nM supernatant
SA317361MINCH_10nM_SN4MINCH 10nM supernatant
SA317362MINCH_10nM_SN2MINCH 10nM supernatant
SA317363MINCH_10nM_SN1MINCH 10nM supernatant
SA317372MINCH_1uM_4MINCH 1µM
SA317373MINCH_1uM_2MINCH 1µM
SA317374MINCH_1uM_1MINCH 1µM
SA317375MINCH_1uM_3MINCH 1µM
SA317376MINCH_1uM_SN4MINCH 1µM supernatant
SA317377MINCH_1uM_SN2MINCH 1µM supernatant
SA317378MINCH_1uM_SN3MINCH 1µM supernatant
SA317379MINCH_1uM_SN1MINCH 1µM supernatant
SA317380MINCH_GW_SN2MINCH GW supernatant
SA317381MINCH_GW_SN4MINCH GW supernatant
SA317382MINCH_GW_SN1MINCH GW supernatant
SA317383MINCH_GW_SN3MINCH GW supernatant
SA317391Rosi_SN1Rosiglitazone supernatant
SA317392Rosi_SN2Rosiglitazone supernatant
SA317393Rosi_SN3Rosiglitazone supernatant
SA317394Rosi_SN4Rosiglitazone supernatant
Showing results 1 to 87 of 87


Collection ID:CO003028
Collection Summary:The SGBS cells were obtained from Prof. Martin Wabitsch laboratory at the University Clinic Ulm. SGBS preadipocytes were differentiated according to the standard protocol described previously (Wabitsch et al., 2001).
Sample Type:Adipose tissue
Storage Conditions:-80℃


Treatment ID:TR003044
Treatment Summary:SGSB preadipocytes were maintained at 37°C and 5% CO2 in 95% humidity. To investigate the effects of the plasticizer DINCH and its primary metabolite MINCH on adipocyte differentiation, SGBS preadipocytes were treated for 12 days with differentiation media without the PPARG agonist rosiglitazone supplemented with DINCH or MINCH (10 nM, 100 nM, 1 µM, and 10 µM). To obtain an adipogenesis reference, SGBS cells were differentiated in the presence of rosiglitazone; to obtain an untreated control, they were differentiated in the absence of rosiglitazone. A final concentration of 0.01% (v/v) MeOH and 0.02% (v/v) DMSO was added to all conditioned differentiation media. Continuous exposure was mimicked by replacing the cell culture medium every second day. Each treatment was performed in four biological replicates (n=4).

Sample Preparation:

Sampleprep ID:SP003041
Sampleprep Summary:Extraction of intracellular and extracellular metabolites was performed by a 1:1:1 methanol:water:chloroform extraction protocol. For the extraction of intracellular metabolites, the culture medium was removed and the cells were rinsed twice with 1 ml of 0.9% ice-cold NaCl. The rinsing solution was removed, and the metabolism of the cells was stopped by adding 400 µL of MeOH (-20 °C) followed by 400 µL of ice-cold H2O containing 10 µM d6-glutarate. Cells were collected using a cell lifter and 400 µL of chloroform was added. After shaking at 1,400 rpm and 4 °C for 20 min, the extraction mixture was centrifuged at 18,000 g and 4 °C for 5 min. Subsequently, 300 µL volume of the polar upper phase was collected and evaporated to complete dryness. For the extraction of extracellular metabolites, 300 µL of the supernatant was extracted by adding 400 µL MeOH (-20 °C) containing 100 nM MEHP, 100 µL ice-cold H2O containing 40 µM d6-glutarate, and 400 µL chloroform (-20 °C). Subsequent sample preparation was identical to the extraction of intracellular metabolites. Note: After measurement of the samples by LC-MS, the raw AUC values uploaded here were normalized to the internal standard (d6-glutarate, if applicable) and DNA content per well (measured by DAPI fluorescence). After normalization, log2 fold changes were calculated by dividing the normalized peak area from each replicate of each treatment by the normalized peak area from each control. Insulin data were not normalized to DAPI because fold changes were calculated by dividing the intensities of the insulin-stimulated cells by the noninsulin-stimulated cells from each treatment.

Combined analysis:

Analysis ID AN004792
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290 Infinity II
Column Waters XSelect XP HSS T3 (150 x 2.1mm, 2.5um)
MS instrument type Triple quadrupole
MS instrument name ABI Sciex 6500+
Units Peak AUC


Chromatography ID:CH003623
Instrument Name:Agilent 1290 Infinity II
Column Name:Waters XSelect XP HSS T3 (150 x 2.1mm, 2.5um)
Column Temperature:40
Flow Gradient:0-5 min 0% B, 5-9 min 0%- 2% B, 9-9.5 min 2-6% B, 9.5-11.5 min 6% B, 11.5-12 min 6-11% B, 12-13.5 min 11% B, 13.5-15.5 min 11-28% B, 15.5-16.5 min 28-53% B, 16.5-22.5 53% B, 22.5-23 min 53-0% B, 23-33 min 0% B
Flow Rate:0-15.5 min 0.4 mL/min, 15.5-16.5 min 0.4-0.15 mL/min, 16.5-23 min 0.15 mL/min, 23-27 min 0.15-0.4 mL/min, 27-33 min 0.4 mL/min
Solvent A:10mM TBA, 10mM acetic acid, 5% MeOH, 2% IPA in water
Solvent B:100% IPA
Chromatography Type:Reversed phase


MS ID:MS004538
Analysis ID:AN004792
Instrument Name:ABI Sciex 6500+
Instrument Type:Triple quadrupole
MS Comments:For identification and quantitation, a scheduled MRM method was used, with specific transitions for every metabolite. Data acquisition and peak integration were performed in Analyst® software (Version 1.7.1).